Press Releases

Jun. 02 Gimv : Quality Guard strengthens its European position with the acquisition of Kooklin. PU
May. 27 Gimv : Report ordinary & special general meeting of May 27, 2026 PU
May. 27 Gimv : Minutes (260527 NTL AV %28ENG%29 website) PU
May. 27 Gimv : Complement Therapeutics Announces Completion of Cohort 1 Dosing and Favourable Independent Data Monitoring Committee Recommendation in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMD PU
May. 27 Gimv : Trading update PU
May. 22 Gimv : Cegeka Acquires Swiss Industry Specialist Lean Projects PU
May. 20 Gimv : TINC- Trading update over the 1Q 2026 PU
May. 07 Gimv : Cegeka Closes 2025 With a Solid Foundation, Ready for Further Growth PU
Apr. 30 New Gimv Anchor investment: acquisition of 5% shareholding in Azelis PU
Apr. 27 Gimv : Convocation annual general meeting of May 27, 2026 PU
Apr. 27 Gimv : CV directors to be (re)appointed (CV%27s bestuurders %28ENG%29) PU
Apr. 23 Gimv : Route description (DOC10 260527 Route description Crowne Plaza %28ENG%29) PU
Mar. 25 Gimv : Complement Therapeutics Announces First Patient Dosed with CTx001 in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMD PU
Mar. 24 Gimv : secures new EUR 400 million revolving credit facility to support accelerated growth ambitions PU
Mar. 11 Gimv : BioConnection is proud to announce its latest investment in further growth PU
Mar. 05 Gimv : Inkoop eigen aandelen afgerond PU
Mar. 05 Gimv : Share buyback finalized PU
Feb. 23 Gimv : Cegeka Appoints Koen Deryckere as New Chief Executive Officer PU
Feb. 20 Gimv : Aankondiging inkoop eigen aandelen in het kader van een aandelenaankoopplan PU
Feb. 20 Gimv : Announcement of share buyback in the context of a share purchase plan PU
Feb. 19 Gimv : zet sterk groeitraject voort met solide resultaten Recordinvesteringen in boekjaar van 9 maanden PU
Feb. 19 Gimv : builds on strong growth to deliver solid results Record investment level in a shortened financial year of 9 months PU
Jan. 26 Gimv : verhoogt focus op strategische doelstellingen en discontinueert activiteiten voor nieuwe Life Sciences investeringen PU
Jan. 26 Gimv : increases focus on strategic objectives and discontinues activities for new Life Sciences investments PU
Jan. 20 Gimv : leidt een Series B investeringsronde van EUR 51 miljoen in Exciva voor verdere ontwikkeling van een innovatieve Alzheimerbehandeling PU
No results match your criteria
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!